Axsome Therapeutics, Inc.

Contributing Author

Recent Articles by Axsome Therapeutics, Inc.

Feb-25	Axsome Therapeutics to Participate in Upcoming Investor Conferences AXSM GlobeNewswire
Feb-24	Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms AXSM GlobeNewswire
Feb-23	Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update AXSM GlobeNewswire
Feb-18	Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference AXSM GlobeNewswire
Feb-17	Axsome Therapeutics Settles SUNOSI (solriamfetol) Patent Litigation with Alkem Laboratories Ltd. AXSM GlobeNewswire
Jan-27	Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23 AXSM GlobeNewswire
Jan-15	Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia AXSM GlobeNewswire
Jan-12	Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue AXSM GlobeNewswire
Dec-31	Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer's Disease Agitation AXSM +22.75% GlobeNewswire
Dec-31	Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission AXSM +22.75% GlobeNewswire
Nov-20	Axsome Therapeutics to Participate in Upcoming Investor Conferences AXSM GlobeNewswire
Nov-06	Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy AXSM GlobeNewswire
Nov-03	Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update AXSM GlobeNewswire
Oct-22	Axsome Therapeutics to Participate in Upcoming Investor Conferences AXSM GlobeNewswire
Oct-09	Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community AXSM GlobeNewswire
Oct-07	Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3 AXSM GlobeNewswire
Sep-17	Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025 AXSM GlobeNewswire
Aug-27	Axsome Therapeutics to Participate in Upcoming Investor Conferences AXSM GlobeNewswire
Aug-04	Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update AXSM GlobeNewswire
Jul-21	Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline AXSM GlobeNewswire
Jul-21	Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today AXSM GlobeNewswire
Jul-09	Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4 AXSM GlobeNewswire
Jul-07	Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21 AXSM GlobeNewswire
Jun-20	Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month AXSM GlobeNewswire
Jun-18	Axsome Therapeutics to Present Data Spanning the SYMBRAVO (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS) AXSM GlobeNewswire
Jun-16	Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders AXSM GlobeNewswire
Jun-11	Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025 AXSM GlobeNewswire
Jun-10	Axsome Therapeutics Announces Availability of SYMBRAVO (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults AXSM GlobeNewswire
Jun-09	Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia AXSM GlobeNewswire
May-29	Axsome Therapeutics to Participate in Upcoming Investor Conferences AXSM GlobeNewswire
May-28	Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting AXSM GlobeNewswire
May-27	Axsome Therapeutics Settles SUNOSI (solriamfetol) Patent Litigation with Hetero Labs Ltd. AXSM GlobeNewswire
May-13	Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone AXSM GlobeNewswire
May-05	Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update AXSM GlobeNewswire

Axsome Therapeutics, Inc.

Recent Articles by Axsome Therapeutics, Inc.

Upgrade your FINVIZ experience